semaglutide aging A new study from UC San Diego offers early clinical evidence that semaglutide, a widely used GLP-1 receptor agonist, may slow biological aging. In a randomized, placebo-controlled trial, researchers observed a 9% Semaglutide - Renew Body Wellness

Hernn, S

doi: 10.1016/j.neubiorev.2024.105561 Summary Keywords schizophrenia, microbiota-gut-brain axis, gut microbiota metabolites, immune dysregulation, neuroinflammation, kynurenine pathway, complement system, toll-like receptors Citation Su B-W, Li Y, Yang L-Y, Yang H-X, Wang W-H, Ren H-W, Bao Y-N, Lao J-Y and Luan Z-L (2025) The role of the microbiota-gut-brain axis in schizophrenia: an immunological perspective

Research suggests that this multi-pathway activation may be better than single target compounds, making it a must have tool for understanding metabolic pathways

Under BALANCE, states can opt in to offer GLP-1 coverage for obesity through their Medicaid programs at reduced federal cost

Sedentary lifestyle